Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.56 |
| ▸ | PI4KA | P42356 | 2/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 14/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418929 | 1.00 | MAP4K4 (0.56) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| Trifluoroacetic Acid SCHEMBL31662344 | 0.84 | EGFR (0.43) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| Trifluoroacetic Acid SCHEMBL29418884 | 0.84 | EGFR (0.43) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4870134 | 0.83 | PI4KA (0.55) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21893449 | 0.83 | PI4KA (0.45) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30165038 | 0.83 | PI4KA (0.45) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29650477 | 0.83 | PI4KA (0.55) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7655336 | 0.75 | EGFR (0.47) | EGFR | |
| SCHEMBL12045623 | 0.75 | EGFR (0.47) | EGFR | |
| SCHEMBL1234859 | 0.75 | PDE4A (0.55) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016154110-A1 | COMPANION DIAGNOSTIC FOR P97 INHIBITOR THERAPY AND METHODS OF USE THEREOF | CLEAVE BIOSCIENCES, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20240376128-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023197984-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | 成都海博为药业有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-1885369-B1 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8859545-B2 | Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases | EVOTEC AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | RENOVIS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-7745451-B2 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | RENOVIS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1885369-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MAP4K4 58/4885PI4KA 351/4885PI4K2B 288/4885 |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | MAP4K4 2945/4885PI4KA 3061/4885PI4K2B 2637/4885 |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | OPRL1, OPRK1, IL1B | MAP4K4 3074/4885PI4KA 3400/4885PI4K2B 3286/4885 |
| US-20240376128-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | CYP4A11, CYP4B1, DHPS | MAP4K4 1446/4885PI4KA 967/4885PI4K2B 1663/4885 |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | MAP4K4 940/4885PI4KA 1779/4885PI4K2B 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.